AM-Pharma
12
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
41.7%
5 terminated/withdrawn out of 12 trials
58.3%
-28.2% vs industry average
8%
1 trials in Phase 3/4
43%
3 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery
Role: lead
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Role: lead
(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Role: lead
Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects
Role: lead
A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
Role: lead
A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia
Role: lead
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
Role: lead
A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis
Role: lead
Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis
Role: lead
A Study in Sepsis Patients With Renal Failure
Role: lead
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis
Role: lead
Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients
Role: lead
All 12 trials loaded